Gilead and Galapagos in Advanced Talks for Autoimmune T Cell Program

Key Facts

1Galapagos and Gilead are in advanced discussions to collaborate on a first-in-class T Cell Engager program.

2The program targets the treatment of autoimmune diseases.

3The potential collaboration follows Gilead's acquisition of Ouro Medicines.

Gilead Sciences and Galapagos NV are in advanced negotiations to collaborate on a novel T Cell Engager program. The partnership aims to develop innovative therapies specifically targeting autoimmune diseases, strengthening both companies' positions in this vital sector. This strategic move follows Gilead's recent acquisition of Ouro Medicines, which provided the foundational assets for the program. Both companies seek to leverage their combined expertise to expand their pipelines in the high-growth immunology market. While the deal is in its final stages and not yet finalized, the market is closely watching for an official announcement. This collaboration is expected to drive innovation in T-cell technology and provide new therapeutic solutions for patients.

Open on chart